Inogen, Inc. (NASDAQ:INGN) Short Interest Down 9.9% in November

Inogen, Inc. (NASDAQ:INGN) saw a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 744,800 shares, a decline of 9.9% from the October 31st total of 826,300 shares. Based on an average daily volume of 192,000 shares, the days-to-cover ratio is presently 3.9 days.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of INGN. Franklin Resources Inc. bought a new stake in shares of Inogen during the 3rd quarter worth $139,000. Virtu Financial LLC bought a new stake in Inogen during the third quarter worth about $111,000. Barclays PLC lifted its stake in Inogen by 72.9% during the third quarter. Barclays PLC now owns 55,508 shares of the medical technology company’s stock worth $539,000 after purchasing an additional 23,398 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Inogen by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company’s stock worth $5,377,000 after purchasing an additional 5,921 shares in the last quarter. Finally, State Street Corp increased its position in shares of Inogen by 2.8% during the 3rd quarter. State Street Corp now owns 511,018 shares of the medical technology company’s stock valued at $4,957,000 after purchasing an additional 14,054 shares during the last quarter. Hedge funds and other institutional investors own 89.94% of the company’s stock.

Inogen Stock Performance

Inogen stock traded up $0.40 during midday trading on Monday, hitting $10.11. 192,878 shares of the company’s stock were exchanged, compared to its average volume of 327,433. The stock has a 50-day moving average price of $9.51 and a two-hundred day moving average price of $9.66. Inogen has a 52-week low of $4.93 and a 52-week high of $13.33. The company has a market cap of $240.82 million, a P/E ratio of -4.49 and a beta of 1.04.

Analyst Upgrades and Downgrades

INGN has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Inogen in a report on Friday, November 8th. StockNews.com cut shares of Inogen from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.